应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
TY Tri-Continental Corp
休市中 03-06 16:00:00 EST
32.47
-0.26
-0.79%
盘后
32.47
+0.00
0.00%
17:16 EST
最高
32.98
最低
32.36
成交量
2.34万
今开
32.56
昨收
32.73
日振幅
1.89%
总市值
16.99亿
流通市值
16.99亿
总股本
5,233万
成交额
76.16万
换手率
0.04%
流通股本
5,233万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
同源康医药-B(02410)：甲磺酸艾多替尼片（TY-9591片）的新药上市申请获国家药品监督管理局受理
智通财经 · 02-06
同源康医药-B(02410)：甲磺酸艾多替尼片（TY-9591片）的新药上市申请获国家药品监督管理局受理
港股异动 | 同源康医药-B(02410)午后涨超4% 甲磺酸艾多替尼片(TY-9591片)拟纳入优先审评
智通财经 · 01-09
港股异动 | 同源康医药-B(02410)午后涨超4% 甲磺酸艾多替尼片(TY-9591片)拟纳入优先审评
同源康医药-B(02410)：甲磺酸艾多替尼片(TY-9591片)拟纳入优先审评
智通财经 · 01-07
同源康医药-B(02410)：甲磺酸艾多替尼片(TY-9591片)拟纳入优先审评
港股异动 | 同源康医药-B(02410)最高涨超10% TY-9591片拟纳入优先审评
智通财经 · 01-07
港股异动 | 同源康医药-B(02410)最高涨超10% TY-9591片拟纳入优先审评
港股异动 | 同源康医药-B(02410)早盘涨超5% 公司正在准备TY-9591附条件上市NDA申请
智通财经 · 2025-12-12
港股异动 | 同源康医药-B(02410)早盘涨超5% 公司正在准备TY-9591附条件上市NDA申请
港股异动 | 同源康医药-B(02410)盘中涨超12% 市场关注核心产品TY-9591进展
智通财经 · 2025-12-05
港股异动 | 同源康医药-B(02410)盘中涨超12% 市场关注核心产品TY-9591进展
港股异动 | 同源康医药-B(02410)早盘一度涨超40% TY-9591关键II期临床试验研究者数据显示达到研究预期
智通财经 · 2025-03-10
港股异动 | 同源康医药-B(02410)早盘一度涨超40% TY-9591关键II期临床试验研究者数据显示达到研究预期
同源康医药TY-9591II期临床试验达到研究预期
财中社 · 2025-03-09
同源康医药TY-9591II期临床试验达到研究预期
【同源康医药-B(02410.HK)：TY-9591对比奥希替尼作为一线治疗EGFR突变肺癌脑转移的关键II期临床试验研究者数据显示达到研究预期，具有统计学显著意义和重大临床获益】同源康医药-B(02410.HK)公布，公司自主研发的TY-9591(商品名：卡达沙®)对比奥希替尼(商品名：泰瑞沙®)作为一线治疗EGFR突变肺癌脑转移的关键 II期临床试验根据研究者数据显示具有统计学显著意义和重大临床获益。主要研究终点颅内客观缓解率(iORR)达到预期目的，TY-9591对比奥希替尼显示出统计学显著意义和临床意义的明显改善，无论在全人群还是在不同亚组人群(包括基因分型、颅内病灶个数、ECOG评分等)中均具有明显统计学差异。
金融界 · 2025-03-09
【同源康医药-B(02410.HK)：TY-9591对比奥希替尼作为一线治疗EGFR突变肺癌脑转移的关键II期临床试验研究者数据显示达到研究预期，具有统计学显著意义和重大临床获益】同源康医药-B(02410.HK)公布，公司自主研发的TY-9591(商品名：卡达沙®)对比奥希替尼(商品名：泰瑞沙®)作为一线治疗EGFR突变肺癌脑转移的关键 II期临床试验根据研究者数据显示具有统计学显著意义和重大临床获益。主要研究终点颅内客观缓解率(iORR)达到预期目的，TY-9591对比奥希替尼显示出统计学显著意义和临床意义的明显改善，无论在全人群还是在不同亚组人群(包括基因分型、颅内病灶个数、ECOG评分等)中均具有明显统计学差异。
同源康医药-B(02410)：TY-9591对比奥希替尼作为一线治疗EGFR突变肺癌脑转移的关键II期临床试验研究者数据显示达到研究预期，具有统计学显著意义和重大临床获益
智通财经 · 2025-03-09
同源康医药-B(02410)：TY-9591对比奥希替尼作为一线治疗EGFR突变肺癌脑转移的关键II期临床试验研究者数据显示达到研究预期，具有统计学显著意义和重大临床获益
港股异动 | 同源康医药-B(02410)午后涨近20%再创新高 核心产品TY-959已获得IND批准
智通财经 · 2024-11-26
港股异动 | 同源康医药-B(02410)午后涨近20%再创新高 核心产品TY-959已获得IND批准
加载更多
公司概况
公司名称：
Tri-Continental Corp
所属市场：
NYSE
上市日期：
--
主营业务：
Tri-Continental Corporation是一家多元化基金。该基金根据1940年《投资公司法》及其修订版（1940年法案）注册为封闭式管理投资公司。
发行价格：
--
{"stockData":{"symbol":"TY","market":"US","secType":"STK","nameCN":"Tri-Continental Corp","latestPrice":32.47,"timestamp":1772830800000,"preClose":32.73,"halted":0,"volume":23375,"hourTrading":{"tag":"盘后","latestPrice":32.47,"preClose":32.47,"latestTime":"17:16 EST","volume":16,"amount":523.3,"timestamp":1772835408976,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.007943782462572503,"floatShares":52329153,"shares":52329153,"eps":4.292493,"marketStatus":"休市中","change":-0.26,"latestTime":"03-06 16:00:00 EST","open":32.56,"high":32.98,"low":32.36,"amount":761579.4725,"amplitude":0.018943,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":4.292493,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1773043200000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":32.73,"dividendRate":0.12037,"preHourTrading":{"tag":"盘前","latestPrice":32.73,"preClose":32.73,"latestTime":"08:05 EST","volume":1,"amount":32.73,"timestamp":1772802316586,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":32.47,"preClose":32.47,"latestTime":"17:16 EST","volume":16,"amount":523.3,"timestamp":1772835408976,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.4753396604487513},"requestUrl":"/m/hq/s/TY","defaultTab":"news","newsList":[{"id":"2609856571","title":"同源康医药-B(02410)：甲磺酸艾多替尼片（TY-9591片）的新药上市申请获国家药品监督管理局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2609856571","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609856571?lang=zh_cn&edition=full","pubTime":"2026-02-06 17:02","pubTimestamp":1770368535,"startTime":"0","endTime":"0","summary":"智通财经APP讯，同源康医药-B 发布公告，本公司在研1类新药甲磺酸艾多替尼片的新药上市申请被国家药品监督管理局药品审评中心受理。甲磺酸艾多替尼片作为奥希替尼的氘代化合物，无论是从化学结构、药理作用、临床有效性和安全性、以及耐药机制分析，甲磺酸艾多替尼片都显示出更明显的临床价值和优势，对疾病的预后有明显改善作用。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1402563.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1515","09939","BK1161","TY","02410","159938"],"gpt_icon":0},{"id":"2602344302","title":"港股异动 | 同源康医药-B(02410)午后涨超4% 甲磺酸艾多替尼片(TY-9591片)拟纳入优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2602344302","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602344302?lang=zh_cn&edition=full","pubTime":"2026-01-09 14:01","pubTimestamp":1767938461,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，同源康医药-B(02410)午后涨超4%，截至发稿，涨3.87%，报14.21港元，成交额5940.29万港元。消息面上，同源康医药发布公告，本公司在研1类新药甲磺酸艾多替尼片(TY-9591片)被国家药品监督管理局(NMPA)药品审评中心拟纳入优先审评品种名单，拟定适应症为：具有表皮生长因子受体(EGFR)外显子19缺失 (19DEL)或外显子21(L858R)置换突变，并伴有中枢神经系统(CNS)转移的局部晚期或转移性非小细胞肺癌(NSCLC)成人患者的一线治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1390815.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1515","02410","159938","BK1161","TY","09939"],"gpt_icon":0},{"id":"2601804835","title":"同源康医药-B(02410)：甲磺酸艾多替尼片(TY-9591片)拟纳入优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2601804835","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601804835?lang=zh_cn&edition=full","pubTime":"2026-01-07 22:49","pubTimestamp":1767797362,"startTime":"0","endTime":"0","summary":"智通财经APP讯，同源康医药-B 发布公告，本公司在研1类新药甲磺酸艾多替尼片被国家药品监督管理局药品审评中心拟纳入优先审评品种名单，拟定适应症为：具有表皮生长因子受体外显子19缺失 或外显子21置换突变，并伴有中枢神经系统转移的局部晚期或转移性非小细胞肺癌成人患者的一线治疗。董事会亦已注意到本公司股份价格及成交量近期出现不寻常波动。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1390102.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09939","BK1515","159938","BK1574","02410","TY","BK1161"],"gpt_icon":0},{"id":"2601942847","title":"港股异动 | 同源康医药-B(02410)最高涨超10% TY-9591片拟纳入优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2601942847","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601942847?lang=zh_cn&edition=full","pubTime":"2026-01-07 09:39","pubTimestamp":1767749996,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，同源康医药-B(02410)涨超10%，截至发稿，涨7.97%，报13.95港元，成交额3266.34万港元。消息面上，1 月 6 日，CDE 官网显示，同源康医药申报的甲磺酸艾多替尼片（TY-9591 片）拟纳入优先审评，用于具有表皮生长因子受体（EGFR）外显子 19 缺失（19DEL）或外显子 21（L858R）置换突变，并伴有中枢神经系统（CNS）转移的局部晚期或转移性非小细胞肺癌（NSCLC）成人患者的一线治疗。值得一提的是，在去年9月份的世界肺癌大会上，同源康医药发布的艾多替尼片针对非小细胞肺癌脑转移关键Ⅱ期临床试验引起同行高度关注。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1389637.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1515","09939","BK1161","TY","02410","159938"],"gpt_icon":0},{"id":"2590292725","title":"港股异动 | 同源康医药-B(02410)早盘涨超5% 公司正在准备TY-9591附条件上市NDA申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2590292725","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590292725?lang=zh_cn&edition=full","pubTime":"2025-12-12 11:00","pubTimestamp":1765508424,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，同源康医药-B早盘涨超5%，截至发稿， 涨3.73%，报13.35港元，成交额2154.6万港元。据悉，艾多替尼片是同源康医药针对EGFR经典突变开发的高选择性小分子抑制剂，公司已于2024年11月完成附条件批准上市资格的224例患者入组，并已于2025年4月提交预上市申请，预计2025年4季度正式提交附条件上市申请。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380751.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","02410","BK1574","BK1161","09939","TY","BK1515"],"gpt_icon":0},{"id":"2589861334","title":"港股异动 | 同源康医药-B(02410)盘中涨超12% 市场关注核心产品TY-9591进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2589861334","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589861334?lang=zh_cn&edition=full","pubTime":"2025-12-05 14:58","pubTimestamp":1764917919,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，同源康医药-B盘中涨超12%，截至发稿，涨7.16%，报14.21港元，成交额1.32亿港元。消息面上，在今年9月份的世界肺癌大会上，同源康医药发布的艾多替尼片针对非小细胞肺癌脑转移关键Ⅱ期临床试验引起同行高度关注。据悉，艾多替尼片是同源康医药针对EGFR经典突变开发的高选择性小分子抑制剂，公司已于2024年11月完成附条件批准上市资格的224例患者入组，并已于2025年4月提交预上市申请，预计2025年4季度正式提交附条件上市申请。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378087.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1515","02410","159938","BK1161","TY","09939"],"gpt_icon":0},{"id":"2518255540","title":"港股异动 | 同源康医药-B(02410)早盘一度涨超40% TY-9591关键II期临床试验研究者数据显示达到研究预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2518255540","media":"智通财经","labels":["dataReport","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518255540?lang=zh_cn&edition=full","pubTime":"2025-03-10 09:34","pubTimestamp":1741570495,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，同源康医药-B早盘一度涨超40%，截至发稿，涨36.93%，报41.9港元，成交额330万港元。消息面上，3月9日，同源康医药-B发布公告，公司自主研发的TY-9591对比奥希替尼作为一线治疗EGFR突变肺癌脑转移的关键II期临床试验根据研究者数据显示具有统计学显著意义和重大临床获益。公司计划于近期向国家药品监督管理局药品审评中心提交NDA上市申请。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1259567.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","09939","TY","BK1574","02410","BK1141","03347","BK1576","BK1161","159938","BK1583"],"gpt_icon":0},{"id":"2518885407","title":"同源康医药TY-9591II期临床试验达到研究预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2518885407","media":"财中社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518885407?lang=zh_cn&edition=full","pubTime":"2025-03-09 19:30","pubTimestamp":1741519833,"startTime":"0","endTime":"0","summary":"3月9日，同源康医药-B（02410）发布公告，宣布其自主研发的TY-9591（商品名：卡达沙?）在对比奥希替尼（商品名：泰瑞沙?）作为一线治疗EGFR突变肺癌脑转移的关键II期临床试验中，达到了研究预期，具有统计学显著意义和重大临床获益。试验结果显示，主要研究终点即颅内客观缓解率(iORR)达到了预期目的，TY-9591在全人群及不同亚组人群中均显示出明显的统计学差异。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202503093340520562.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","BK1141","03347","BK1583","TY","BK1576","09939","BK1515","BK1161"],"gpt_icon":0},{"id":"2518684402","title":"【同源康医药-B(02410.HK)：TY-9591对比奥希替尼作为一线治疗EGFR突变肺癌脑转移的关键II期临床试验研究者数据显示达到研究预期，具有统计学显著意义和重大临床获益】同源康医药-B(02410.HK)公布，公司自主研发的TY-9591(商品名：卡达沙®)对比奥希替尼(商品名：泰瑞沙®)作为一线治疗EGFR突变肺癌脑转移的关键 II期临床试验根据研究者数据显示具有统计学显著意义和重大临床获益。主要研究终点颅内客观缓解率(iORR)达到预期目的，TY-9591对比奥希替尼显示出统计学显著意义和临床意义的明显改善，无论在全人群还是在不同亚组人群(包括基因分型、颅内病灶个数、ECOG评分等)中均具有明显统计学差异。","url":"https://stock-news.laohu8.com/highlight/detail?id=2518684402","media":"金融界","labels":["productRelease","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518684402?lang=zh_cn&edition=full","pubTime":"2025-03-09 19:12","pubTimestamp":1741518744,"startTime":"0","endTime":"0","summary":"同源康医药-B(02410.HK)公布，公司自主研发的TY-9591(商品名：卡达沙®)对比奥希替尼(商品名：泰瑞沙®)作为一线治疗EGFR突变肺癌脑转移的关键 II期临床试验根据研究者数据显示具有统计学显著意义和重大临床获益。主要研究终点颅内客观缓解率(iORR)达到预期目的，TY-9591对比奥希替尼显示出统计学显著意义和临床意义的明显改善，无论在全人群还是在不同亚组人群(包括基因分型、颅内病灶个数、ECOG评分等)中均具有明显统计学差异。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/09191248615055.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","159938","BK1515","BK1574","BK1583","02410","BK1576","TY","09939","BK1141","03347"],"gpt_icon":0},{"id":"2518440289","title":"同源康医药-B(02410)：TY-9591对比奥希替尼作为一线治疗EGFR突变肺癌脑转移的关键II期临床试验研究者数据显示达到研究预期，具有统计学显著意义和重大临床获益","url":"https://stock-news.laohu8.com/highlight/detail?id=2518440289","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518440289?lang=zh_cn&edition=full","pubTime":"2025-03-09 19:07","pubTimestamp":1741518432,"startTime":"0","endTime":"0","summary":"智通财经APP讯，同源康医药-B(02410)公布，公司自主研发的TY-9591(商品名：卡达沙®)对比奥希替尼(商品名：泰瑞沙®)作为一线治疗EGFR突变肺癌脑转移的关键 II期临床试验根据研究者数据显示具有统计学显著意义和重大临床获益。主要研究终点颅内客观缓解率(iORR)达到预期目的，TY-9591对比奥希替尼显示出统计学显著意义和临床意义的明显改善，无论在全人群还是在不同亚组人群(包括基因分型、颅内病灶个数、ECOG评分等)中均具有明显统计学差异。公司计划于近期向国家药品监督管理局药品审评中心(CDE)提交NDA (New Drug Application)上市申请。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1259496.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","159938","BK1515","BK1574","BK1583","02410","BK1576","TY","09939","BK1141","03347"],"gpt_icon":0},{"id":"2486336041","title":"港股异动 | 同源康医药-B(02410)午后涨近20%再创新高 核心产品TY-959已获得IND批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2486336041","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486336041?lang=zh_cn&edition=full","pubTime":"2024-11-26 14:57","pubTimestamp":1732604248,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，同源康医药-B午后涨近20%，高见38.5港元，创上市新高，较招股价12.1港元已涨超2倍。截至发稿，涨11.52%，报34.85港元，成交额1189.25万港元。据悉，公司已建立由11款候选药物组成的管线，包括2个低风险产品TY-9591、TY-302，5款创新临床产品，4款处于临床前阶段的产品。值得注意的是，公司已获得国家药监局对其核心产品TY-9591的II期和III期临床试验的IND批准，同时正在进行产品TY-302和TY-2136b的关键临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1215901.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","TY","159938","BK1574","09939","BK1161","02410"],"gpt_icon":0}],"profile":{"websiteUrl":"http://columbiathreadneedleus.com","stockEarnings":[{"period":"1week","weight":-0.0187},{"period":"1month","weight":-0.019},{"period":"3month","weight":-0.0664},{"period":"6month","weight":-0.0322},{"period":"1year","weight":0.0404},{"period":"ytd","weight":-0.0058}],"compareEarnings":[{"period":"1week","weight":-0.0198},{"period":"1month","weight":-0.0201},{"period":"3month","weight":-0.0194},{"period":"6month","weight":0.0388},{"period":"1year","weight":0.174},{"period":"ytd","weight":-0.014}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Tri-Continental Corporation是一家多元化基金。该基金根据1940年《投资公司法》及其修订版（1940年法案）注册为封闭式管理投资公司。","yearOnYearQuotes":[{"month":1,"riseRate":0.586957,"avgChangeRate":-0.00053},{"month":2,"riseRate":0.565217,"avgChangeRate":0.005029},{"month":3,"riseRate":0.478261,"avgChangeRate":-0.001608},{"month":4,"riseRate":0.630435,"avgChangeRate":0.01469},{"month":5,"riseRate":0.695652,"avgChangeRate":0.016673},{"month":6,"riseRate":0.434783,"avgChangeRate":-0.00859},{"month":7,"riseRate":0.586957,"avgChangeRate":0.012012},{"month":8,"riseRate":0.586957,"avgChangeRate":0.005245},{"month":9,"riseRate":0.413043,"avgChangeRate":-0.012486},{"month":10,"riseRate":0.630435,"avgChangeRate":0.006568},{"month":11,"riseRate":0.695652,"avgChangeRate":0.018679},{"month":12,"riseRate":0.391304,"avgChangeRate":-0.026047}],"exchange":"NYSE","name":"Tri-Continental Corp","nameEN":"Tri-Continental Corporation"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Tri-Continental Corp(TY)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Tri-Continental Corp(TY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Tri-Continental Corp,TY,Tri-Continental Corp股票,Tri-Continental Corp股票老虎,Tri-Continental Corp股票老虎国际,Tri-Continental Corp行情,Tri-Continental Corp股票行情,Tri-Continental Corp股价,Tri-Continental Corp股市,Tri-Continental Corp股票价格,Tri-Continental Corp股票交易,Tri-Continental Corp股票购买,Tri-Continental Corp股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Tri-Continental Corp(TY)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Tri-Continental Corp(TY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}